<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961138</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01</org_study_id>
    <nct_id>NCT04961138</nct_id>
  </id_info>
  <brief_title>Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma</brief_title>
  <official_title>Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma: an Open, Random, Multicenter, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of present study is to evaluate whether per-operative neoadjuvant therapy&#xD;
      combined with surgery could improve the 1-year disease-free survival of stage III&#xD;
      hepatocellular carcinoma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year disease free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of R0 resection</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Hepatocellular Carcinoma Stage III</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transhepatic Arterial Chemotherapy And Embolization (TACE)</intervention_name>
    <description>Receiving TACE and lenvatinib before surgery.</description>
    <arm_group_label>Neoadjuvant group</arm_group_label>
    <other_name>lenvatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Removing tumor by surgery.</description>
    <arm_group_label>Surgery group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years old, both gender&#xD;
&#xD;
          -  Confirmed diagnosis of stage III hepatocellular carcinoma(HCC)&#xD;
&#xD;
          -  Fulfill the criteria of surgery&#xD;
&#xD;
          -  No other severe comorbidity&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group score(ECOG) 0-2&#xD;
&#xD;
          -  Expected survival &gt; 3months&#xD;
&#xD;
          -  Informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received chemoradiotherapy or other antineoplastic drugs&#xD;
&#xD;
          -  Severe cirrhosis with Child-Pugh score &gt;10&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 times upper limit, AST or ALT &gt; 2times upper limit, indocyanine&#xD;
             green retention rate after 15 min(ICG15) &gt;=40%;&#xD;
&#xD;
          -  Not fulfill the surgery criteria&#xD;
&#xD;
          -  Received major surgery within 1month&#xD;
&#xD;
          -  History of other tumor&#xD;
&#xD;
          -  Participate other clinical trial within 1month&#xD;
&#xD;
          -  Drug or alcohol abuse, AIDS&#xD;
&#xD;
          -  Uncontrollable epileptic seizure or cognitive disorder&#xD;
&#xD;
          -  Severe allergy&#xD;
&#xD;
          -  Other unsuitable conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuan Ding, MD</last_name>
    <phone>+8618858101960</phone>
    <email>dingyuandy@126.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

